The Role of Genistein and its Derivatives in Ovarian Cancer: New Perspectives for Molecular Mechanisms and Clinical Applications

Genistein (GEN) is a member of the polyphenol family, known chiefly for its effects on metabolic diseases and gynecological disorders. GEN has anti-cancer properties by inhibiting tumor proliferation, tumor metastasis, invasion, migration, and inducing apoptosis. Ovarian cancer (OC) is ranked 7th among the most common gynecological cancers. Despite its low incidence compared to other cancers, it is the first cause of death among gynecologic malignancies. Surgery and chemotherapy are the main options for treating this fatal cancer. Therefore, further investigations into GEN may aid in the discovery of novel therapeutics for preventing and/or treating OC. In this review, we aim to investigate the role of GEN in ovarian cancer. We investigate the anti-tumor effects of GEN on OC cell lines, including inducing apoptosis, suppressing tumor growth, and inhibiting metastasis. Also, we review the studies investigating GEN's roles as an adjuvant in therapeutic regimens with other chemotherapeutic agents (e.g., cisplatin, quercetin, and gemcitabine).

Genistein, apoptosis, ovarian cancer, endometriosis, gynecological cancers, fatty acids. [1] Jaiswal, N.; Akhtar, J.; Singh, S.P.; Ahsan, F. An overview on genistein and its various formulations. Drug Res. (Stuttg.), 2019, 69(6), 305-313. [http://dx.doi.org/10.1055/a-0797-3657] [PMID: 30517965] [http://dx.doi.org/10.1055/a-0797-3657] [PMID: 30517965] [2] Mukund, V.; Mukund, D.; Sharma, V.; Mannarapu, M.; Alam, A. Genistein: Its role in metabolic diseases and cancer. Crit. Rev. Oncol. Hematol., 2017, 119, 13-22. [http://dx.doi.org/10.1016/j.critrevonc.2017.09.004] [PMID: 29065980] [http://dx.doi.org/10.1016/j.critrevonc.2017.09.004] [PMID: 29065980] [3] Mukund, V. Genistein: Its role in breast cancer growth and metastasis. Curr. Drug Metab., 2020, 21(1), 6-10. [http://dx.doi.org/10.2174/1389200221666200120121919] [PMID: 31987018] [http://dx.doi.org/10.2174/1389200221666200120121919] [PMID: 31987018] [4] Fu, Z.; Cao, X.; Liu, L.; Cao, X.; Cui, Y.; Li, X.; Quan, M.; Ren, K.; Chen, A.; Xu, C.; Qiu, Y.; Chen, X.; Wang, Z.; Cao, J. Genistein inhibits lung cancer cell stem-like characteristics by modulating MnSOD and FoxM1 expression. Oncol. Lett., 2020, 20(3), 2506-2515. [http://dx.doi.org/10.3892/ol.2020.11802] [PMID: 32782570] [http://dx.doi.org/10.3892/ol.2020.11802] [PMID: 32782570] [5] Zhang, Q.; Bao, J.; Yang, J. Genistein-triggered anticancer activity against liver cancer cell line HepG2 involves ROS generation, mitochondrial apoptosis, G2/M cell cycle arrest and inhibition of cell migrationand inhibition of cell migration. Arch. Med. Sci., 2019, 15(4), 1001-1009. [http://dx.doi.org/10.5114/aoms.2018.78742] [PMID: 31360194] [http://dx.doi.org/10.5114/aoms.2018.78742] [PMID: 31360194] [6] Chen, C.; Wang, Y.; Chen, S.; Ruan, X.; Liao, H.; Zhang, Y.; Sun, J.; Gao, J.; Deng, G. Genistein inhibits migration and invasion of cervical cancer HeLa cells by regulating FAK-paxillin and MAPK signaling pathways. Taiwan. J. Obstet. Gynecol., 2020, 59(3), 403-408. [http://dx.doi.org/10.1016/j.tjog.2020.03.012] [PMID: 32416888] [http://dx.doi.org/10.1016/j.tjog.2020.03.012] [PMID: 32416888] [7] Momenimovahed, Z.; Tiznobaik, A.; Taheri, S.; Salehiniya, H. Ovarian cancer in the world: Epidemiology and risk factors. Int. J. Womens Health, 2019, 11, 287-299. [http://dx.doi.org/10.2147/IJWH.S197604] [PMID: 31118829] [http://dx.doi.org/10.2147/IJWH.S197604] [PMID: 31118829] [8] Orr, B.; Edwards, R.P. Diagnosis and treatment of ovarian cancer. Hematol. Oncol. Clin. North Am., 2018, 32(6), 943-964. [http://dx.doi.org/10.1016/j.hoc.2018.07.010] [PMID: 30390767] [http://dx.doi.org/10.1016/j.hoc.2018.07.010] [PMID: 30390767] [9] Yang, Z.; Zhu, W.; Gao, S.; Xu, H.; Wu, B.; Kulkarni, K.; Singh, R.; Tang, L.; Hu, M. Simultaneous determination of genistein and its four phase II metabolites in blood by a sensitive and robust UPLC–MS/MS method: Application to an oral bioavailability study of genistein in mice. J. Pharm. Biomed. Anal., 2010, 53(1), 81-89. [http://dx.doi.org/10.1016/j.jpba.2010.03.011] [PMID: 20378296] [http://dx.doi.org/10.1016/j.jpba.2010.03.011] [PMID: 20378296] [10] Zhou, S.; Hu, Y.; Zhang, B.; Teng, Z.; Gan, H.; Yang, Z.; Wang, Q.; Huan, M.; Mei, Q. Dose-dependent absorption, metabolism, and excretion of genistein in rats. J. Agric. Food Chem., 2008, 56(18), 8354-8359. [http://dx.doi.org/10.1021/jf801051d] [PMID: 18710250] [http://dx.doi.org/10.1021/jf801051d] [PMID: 18710250] [11] Andrade, J.E.; Twaddle, N.C.; Helferich, W.G.; Doerge, D.R. Absolute bioavailability of isoflavones from soy protein isolate-containing food in female BALB/c mice. J. Agric. Food Chem., 2010, 58(7), 4529-4536. [http://dx.doi.org/10.1021/jf9039843] [PMID: 20225898] [http://dx.doi.org/10.1021/jf9039843] [PMID: 20225898] [12] Coldham, N.G.; Zhang, A.Q.; Key, P.; Sauer, M.J. Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity. Eur. J. Drug Metab. Pharmacokinet., 2002, 27(4), 249-258. [http://dx.doi.org/10.1007/BF03192335] [PMID: 12587954] [http://dx.doi.org/10.1007/BF03192335] [PMID: 12587954] [13] Setchell, K.D.R.; Brown, N.M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B.E.; Brashear, W.T.; Kirschner, A.S.; Cassidy, A.; Heubi, J.E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr., 2001, 131(4)(Suppl.), 1362S-1375S. [http://dx.doi.org/10.1093/jn/131.4.1362S] [PMID: 11285356] [http://dx.doi.org/10.1093/jn/131.4.1362S] [PMID: 11285356] [14] Gu, L.; House, S.E.; Prior, R.L.; Fang, N.; Ronis, M.J.J.; Clarkson, T.B.; Wilson, M.E.; Badger, T.M. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J. Nutr., 2006, 136(5), 1215-1221. [http://dx.doi.org/10.1093/jn/136.5.1215] [PMID: 16614407] [http://dx.doi.org/10.1093/jn/136.5.1215] [PMID: 16614407] [15] Shelnutt, S.R.; Cimino, C.O.; Wiggins, P.A.; Badger, T.M. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol. Biomarkers Prev., 2000, 9(4), 413-419. [PMID: 10794486] [PMID: 10794486] [16] Adlercreutz, H.; van der Wildt, J.; Kinzel, J.; Attalla, H.; Wähäla, K.; Mäkelä, T.; Hase, T.; Fotsis, T. Lignan and isoflavonoid conjugates in human urine. J. Steroid Biochem. Mol. Biol., 1995, 52(1), 97-103. [http://dx.doi.org/10.1016/0960-0760(94)00146-D] [PMID: 7857879] [http://dx.doi.org/10.1016/0960-0760(94)00146-D] [PMID: 7857879] [17] Fischer, L.; Mahoney, C.; Jeffcoat, A.R.; Koch, M.A.; Thomas, B.F.; Valentine, J.L.; Stinchcombe, T.; Boan, J.; Crowell, J.A.; Zeisel, S.H. Clinical characteristics and pharmacokinetics of purified soy isoflavones: Multiple-dose administration to men with prostate neoplasia. Nutr. Cancer, 2004, 48(2), 160-170. [http://dx.doi.org/10.1207/s15327914nc4802_5] [PMID: 15231450] [http://dx.doi.org/10.1207/s15327914nc4802_5] [PMID: 15231450] [18] Goh, Y.X.; Jalil, J.; Lam, K.W.; Husain, K.; Premakumar, C.M. Genistein: A review on its anti-inflammatory properties. Front. Pharmacol., 2022, 13, 820969. [http://dx.doi.org/10.3389/fphar.2022.820969] [PMID: 35140617] [http://dx.doi.org/10.3389/fphar.2022.820969] [PMID: 35140617] [19] Tuli, H.S.; Tuorkey, M.J.; Thakral, F.; Sak, K.; Kumar, M.; Sharma, A.K.; Sharma, U.; Jain, A.; Aggarwal, V.; Bishayee, A. Molecular mechanisms of action of genistein in cancer: Recent advances. Front. Pharmacol., 2019, 10, 1336. [http://dx.doi.org/10.3389/fphar.2019.01336] [PMID: 31866857] [http://dx.doi.org/10.3389/fphar.2019.01336] [PMID: 31866857] [20] Yang, Z.; Kulkarni, K.; Zhu, W.; Hu, M. Bioavailability and pharmacokinetics of genistein: Mechanistic studies on its ADME. Anticancer. Agents Med. Chem., 2012, 12(10), 1264-1280. [http://dx.doi.org/10.2174/187152012803833107] [PMID: 22583407] [http://dx.doi.org/10.2174/187152012803833107] [PMID: 22583407] [21] Kano, M.; Takayanagi, T.; Harada, K.; Sawada, S.; Ishikawa, F. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J. Nutr., 2006, 136(9), 2291-2296. [http://dx.doi.org/10.1093/jn/136.9.2291] [PMID: 16920843] [http://dx.doi.org/10.1093/jn/136.9.2291] [PMID: 16920843] [22] Papaj, K.; Kasprzycka, A.; Góra, A.; Grajoszek, A.; Rzepecka, G.; Stojko, J.; Barski, J.J.; Szeja, W.; Rusin, A. Structure–bioavailability relationship study of genistein derivatives with antiproliferative activity on human cancer cell. J. Pharm. Biomed. Anal., 2020, 185, 113216. [http://dx.doi.org/10.1016/j.jpba.2020.113216] [PMID: 32155543] [http://dx.doi.org/10.1016/j.jpba.2020.113216] [PMID: 32155543] [23] Rusin, A.; Krawczyk, Z.; Grynkiewicz, G.; Gogler, A.; Zawisza-Puchałka, J.; Szeja, W. Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim. Pol., 2010, 57(1), 23-34. [http://dx.doi.org/10.18388/abp.2010_2368] [PMID: 20216977] [http://dx.doi.org/10.18388/abp.2010_2368] [PMID: 20216977] [24] Byczek, A.; Zawisza-Puchalka, J.; Gruca, A.; Papaj, K.; Grynkiewicz, G.; Rusin, M.; Szeja, W.; Rusin, A. Genistein derivatives regioisomerically substituted at 7-O- and 4′-O- have different effect on the cell cycle. J. Chem., 2013. [http://dx.doi.org/10.1155/2013/191563] [http://dx.doi.org/10.1155/2013/191563] [25] Szeja, W.; Grynkiewicz, G.; Bieg, T.; Swierk, P.; Byczek, A.; Papaj, K.; Kitel, R.; Rusin, A. Synthesis and cytotoxicity of 2,3-enopyranosyl C-linked conjugates of genistein. Molecules, 2014, 19(6), 7072-7093. [http://dx.doi.org/10.3390/molecules19067072] [PMID: 24886936] [http://dx.doi.org/10.3390/molecules19067072] [PMID: 24886936] [26] Kim, S.H.; Kim, C.W.; Jeon, S.Y.; Go, R.E.; Hwang, K.A.; Choi, K.C. Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Lab. Anim. Res., 2014, 30(4), 143-150. [http://dx.doi.org/10.5625/lar.2014.30.4.143] [PMID: 25628724] [http://dx.doi.org/10.5625/lar.2014.30.4.143] [PMID: 25628724] [27] Mahmoud, A.M.; Yang, W.; Bosland, M.C. Soy isoflavones and prostate cancer: A review of molecular mechanisms. J. Steroid Biochem. Mol. Biol., 2014, 140, 116-132. [http://dx.doi.org/10.1016/j.jsbmb.2013.12.010] [PMID: 24373791] [http://dx.doi.org/10.1016/j.jsbmb.2013.12.010] [PMID: 24373791] [28] Spagnuolo, C.; Russo, G.L.; Orhan, I.E.; Habtemariam, S.; Daglia, M.; Sureda, A.; Nabavi, S.F.; Devi, K.P.; Loizzo, M.R.; Tundis, R.; Nabavi, S.M. Genistein and cancer: Current status, challenges, and future directions. Adv. Nutr., 2015, 6(4), 408-419. [http://dx.doi.org/10.3945/an.114.008052] [PMID: 26178025] [http://dx.doi.org/10.3945/an.114.008052] [PMID: 26178025] [29] Bhat, S.S.; Prasad, S.K.; Shivamallu, C.; Prasad, K.S.; Syed, A.; Reddy, P.; Cull, C.A.; Amachawadi, R.G. Genistein: A potent anti-breast cancer agent. Curr. Issues Mol. Biol., 2021, 43(3), 1502-1517. [http://dx.doi.org/10.3390/cimb43030106] [PMID: 34698063] [http://dx.doi.org/10.3390/cimb43030106] [PMID: 34698063] [30] Kobayashi, T.; Nakata, T.; Kuzumaki, T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett., 2002, 176(1), 17-23. [http://dx.doi.org/10.1016/S0304-3835(01)00738-8] [PMID: 11790449] [http://dx.doi.org/10.1016/S0304-3835(01)00738-8] [PMID: 11790449] [31] Ye, F.; Wu, J.; Dunn, T.; Yi, J.; Tong, X.; Zhang, D. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett., 2004, 211(1), 39-46. [http://dx.doi.org/10.1016/j.canlet.2004.03.043] [PMID: 15194215] [http://dx.doi.org/10.1016/j.canlet.2004.03.043] [PMID: 15194215] [32] Alhasan, S.A.; Aranha, O.; Sarkar, F.H. Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin. Cancer Res., 2001, 7(12), 4174-4181. [PMID: 11751518] [PMID: 11751518] [33] Sahin, K.; Yenice, E.; Bilir, B.; Orhan, C.; Tuzcu, M.; Sahin, N.; Ozercan, I.H.; Kabil, N.; Ozpolat, B.; Kucuk, O. Genistein prevents development of spontaneous ovarian cancer and inhibits tumor growth in hen model. Cancer Prev. Res. (Phila.), 2019, 12(3), 135-146. [http://dx.doi.org/10.1158/1940-6207.CAPR-17-0289] [PMID: 30651293] [http://dx.doi.org/10.1158/1940-6207.CAPR-17-0289] [PMID: 30651293] [34] Lu, C.; Wang, Y.; Xu, T.; Li, Q.; Wang, D.; Zhang, L.; Fan, B.; Wang, F.; Liu, X. Genistein ameliorates scopolamine-induced amnesia in mice through the regulation of the cholinergic neurotransmission, antioxidant system and the ERK/CREB/BDNF signaling. Front. Pharmacol., 2018, 9, 1153. [http://dx.doi.org/10.3389/fphar.2018.01153] [PMID: 30369882] [http://dx.doi.org/10.3389/fphar.2018.01153] [PMID: 30369882] [35] Carbonel, A.A.F.; Simões, R.S.; Girão, J.H.C.; Sasso, G.; Bertoncini, C.R.A.; Sorpreso, I.C.E. Isoflavones in gynecology. Rev. Assoc. Med. Bras., 2018, 64(6), 560-4. [http://dx.doi.org/10.1590/1806-9282.64.06.560] [http://dx.doi.org/10.1590/1806-9282.64.06.560] [36] Kuiper, G.G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 1996, 93(12), 5925-5930. [http://dx.doi.org/10.1073/pnas.93.12.5925] [PMID: 8650195] [http://dx.doi.org/10.1073/pnas.93.12.5925] [PMID: 8650195] [37] Cassidy, A.; de Pascual Teresa, S.; Rimbach, G. Molecular mechanisms by which dietary isoflavones potentially prevent atherosclerosis. Expert Rev. Mol. Med., 2003, 5(24), 1-15. [http://dx.doi.org/10.1017/S1462399403006732] [PMID: 14585174] [http://dx.doi.org/10.1017/S1462399403006732] [PMID: 14585174] [38] Nilsson, S.; Koehler, K.F.; Gustafsson, J.Å. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov., 2011, 10(10), 778-792. [http://dx.doi.org/10.1038/nrd3551] [PMID: 21921919] [http://dx.doi.org/10.1038/nrd3551] [PMID: 21921919] [39] Minutolo, F.; Macchia, M.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Estrogen receptor β ligands: Recent advances and biomedical applications. Med. Res. Rev., 2011, 31(3), 364-442. [http://dx.doi.org/10.1002/med.20186] [PMID: 19967775] [http://dx.doi.org/10.1002/med.20186] [PMID: 19967775] [40] Yonekubo, S.; Fushimi, N.; Miyagi, T.; Nakanishi, O.; Katsuno, K.; Ozawa, M.; Handa, C.; Furuya, N.; Muranaka, H. Synthesis and structure–activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta. Bioorg. Med. Chem., 2016, 24(22), 5895-5910. [http://dx.doi.org/10.1016/j.bmc.2016.09.047] [PMID: 27692995] [http://dx.doi.org/10.1016/j.bmc.2016.09.047] [PMID: 27692995] [41] Chan, K.K.L.; Leung, T.H.Y.; Chan, D.W.; Wei, N.; Lau, G.T.Y.; Liu, S.S.; Siu, M.K.Y.; Ngan, H.Y.S. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer. J. Endocrinol., 2014, 221(2), 325-336. [http://dx.doi.org/10.1530/JOE-13-0500] [PMID: 24819599] [http://dx.doi.org/10.1530/JOE-13-0500] [PMID: 24819599] [42] Harris, H.A. Preclinical characterization of selective estrogen receptor beta agonists: New insights into their therapeutic potential. Ernst. Schering. Found. Symp. Proc., 2006, 2006(1), 149-61. [43] Chaudhary, S.C.; Singh, T.; Talwelkar, S.S.; Srivastava, R.K.; Arumugam, A.; Weng, Z.; Elmets, C.A.; Afaq, F.; Kopelovich, L.; Athar, M. Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev. Res. (Phila.), 2014, 7(2), 186-198. [http://dx.doi.org/10.1158/1940-6207.CAPR-13-0276] [PMID: 24217507] [http://dx.doi.org/10.1158/1940-6207.CAPR-13-0276] [PMID: 24217507] [44] Schüler-Toprak, S.; Häring, J.; Inwald, E.C.; Moehle, C.; Ortmann, O.; Treeck, O. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer, 2016, 16(1), 951. [http://dx.doi.org/10.1186/s12885-016-2973-y] [PMID: 28003019] [http://dx.doi.org/10.1186/s12885-016-2973-y] [PMID: 28003019] [45] Schüler-Toprak, S.; Moehle, C.; Skrzypczak, M.; Ortmann, O.; Treeck, O. Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells. BMC Cancer, 2017, 17(1), 319. [http://dx.doi.org/10.1186/s12885-017-3246-0] [PMID: 28482871] [http://dx.doi.org/10.1186/s12885-017-3246-0] [PMID: 28482871] [46] Chan, K.K.L.; Siu, M.K.Y.; Jiang, Y.; Wang, J.; Leung, T.H.Y.; Ngan, H.Y.S. Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell Int., 2018, 18(1), 65. [http://dx.doi.org/10.1186/s12935-018-0559-2] [PMID: 29743815] [http://dx.doi.org/10.1186/s12935-018-0559-2] [PMID: 29743815] [47] Haddad, Y.H.; Said, R.S.; Kamel, R.; Morsy, E.M.E.; El-Demerdash, E. Phytoestrogen genistein hinders ovarian oxidative damage and apoptotic cell death-induced by ionizing radiation: Co-operative role of ER-β, TGF-β, and FOXL-2. Sci. Rep., 2020, 10(1), 13551. [http://dx.doi.org/10.1038/s41598-020-70309-2] [PMID: 32782329] [http://dx.doi.org/10.1038/s41598-020-70309-2] [PMID: 32782329] [48] Sutrisno, S.; Aprina, H.; Simanungkalit, H.M.; Andriyani, A.; Barlianto, W.; Sujuti, H.; Santoso, S.; Dwijayasa, P.M.; Wahyuni, E.S.; Mustofa, E. Genistein modulates the estrogen receptor and suppresses angiogenesis and inflammation in the murine model of peritoneal endometriosis. J. Tradit. Complement. Med., 2018, 8(2), 278-281. [http://dx.doi.org/10.1016/j.jtcme.2017.03.002] [PMID: 29736382] [http://dx.doi.org/10.1016/j.jtcme.2017.03.002] [PMID: 29736382] [49] Tsuchiya, M.; Miura, T.; Hanaoka, T.; Iwasaki, M.; Sasaki, H.; Tanaka, T.; Nakao, H.; Katoh, T.; Ikenoue, T.; Kabuto, M.; Tsugane, S. Effect of soy isoflavones on endometriosis: Interaction with estrogen receptor 2 gene polymorphism. Epidemiology, 2007, 18(3), 402-408. [http://dx.doi.org/10.1097/01.ede.0000257571.01358.f9] [PMID: 17474167] [http://dx.doi.org/10.1097/01.ede.0000257571.01358.f9] [PMID: 17474167] [50] Mumford, S.L.; Weck, J.; Kannan, K.; Buck Louis, G.M. Urinary phytoestrogen concentrations are not associated with incident endometriosis in premenopausal women. J. Nutr., 2017, 147(2), 227-234. [http://dx.doi.org/10.3945/jn.116.238840] [PMID: 28031375] [http://dx.doi.org/10.3945/jn.116.238840] [PMID: 28031375] [51] Zhao, Q.; Zhao, M.; Parris, A.B.; Xing, Y.; Yang, X. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells. Int. J. Oncol., 2016, 49(3), 1203-1210. [http://dx.doi.org/10.3892/ijo.2016.3588] [PMID: 27574003] [http://dx.doi.org/10.3892/ijo.2016.3588] [PMID: 27574003] [52] Pons, D.G.; Nadal-Serrano, M.; Torrens-Mas, M.; Oliver, J.; Roca, P. The phytoestrogen genistein affects breast cancer cells treatment depending on the ERα/ERβ ratio. J. Cell. Biochem., 2016, 117(1), 218-229. [http://dx.doi.org/10.1002/jcb.25268] [PMID: 26100284] [http://dx.doi.org/10.1002/jcb.25268] [PMID: 26100284] [53] Sundaram, M.K.; Ansari, M.Z.; Al Mutery, A.; Ashraf, M.; Nasab, R.; Rai, S.; Rais, N.; Hussain, A. Genistein induces alterations of epigenetic modulatory signatures in human cervical cancer cells. Anticancer. Agents Med. Chem., 2018, 18(3), 412-421. [http://dx.doi.org/10.2174/1871520617666170918142114] [PMID: 28925878] [http://dx.doi.org/10.2174/1871520617666170918142114] [PMID: 28925878] [54] Gossner, G.; Choi, M.; Tan, L.; Fogoros, S.; Griffith, K.; Kuenker, M.; Liu, J. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol. Oncol., 2007, 105(1), 23-30. [http://dx.doi.org/10.1016/j.ygyno.2006.11.009] [PMID: 17234261] [http://dx.doi.org/10.1016/j.ygyno.2006.11.009] [PMID: 17234261] [55] Ouyang, G.; Yao, L.; Ruan, K.; Song, G.; Mao, Y.; Bao, S. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol. Int., 2009, 33(12), 1237-1244. [http://dx.doi.org/10.1016/j.cellbi.2009.08.011] [PMID: 19732843] [http://dx.doi.org/10.1016/j.cellbi.2009.08.011] [PMID: 19732843] [56] Abraham, R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 2001, 15(17), 2177-2196. [http://dx.doi.org/10.1101/gad.914401] [PMID: 11544175] [http://dx.doi.org/10.1101/gad.914401] [PMID: 11544175] [57] Thasni, K.A.A.; Rojini, G.; Rakesh, S.N.; Ratheeshkumar, T.; Babu, M.S.; Srinivas, G.; Banerji, A.; Srinivas, P. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on breast cancer susceptibility gene-1 (BRCA1) status. Eur. J. Pharmacol., 2008, 588(2-3), 158-164. [http://dx.doi.org/10.1016/j.ejphar.2008.04.041] [PMID: 18514188] [http://dx.doi.org/10.1016/j.ejphar.2008.04.041] [PMID: 18514188] [58] Erten, F.; Yeni̇ce, E.; Orhan, C.; Er, B.; Demi̇rel Öner, P.; Defo Deeh, P.B.; Şahi̇n, K. Genistein suppresses the inflammation and GSK-3 pathway in an animal model of spontaneous ovarian cancer. Turk. J. Med. Sci., 2021, 51(3), 1465-1471. [http://dx.doi.org/10.3906/sag-2007-254] [PMID: 33550763] [http://dx.doi.org/10.3906/sag-2007-254] [PMID: 33550763] [59] Huang, S.L.; Chang, T.C.; Chao, C.C.K.; Sun, N.K. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells. Biochem. Pharmacol., 2020, 177, 113965. [http://dx.doi.org/10.1016/j.bcp.2020.113965] [PMID: 32278794] [http://dx.doi.org/10.1016/j.bcp.2020.113965] [PMID: 32278794] [60] Ning, Y.; Feng, W.; Cao, X.; Ren, K.; Quan, M.; Chen, A.; Xu, C.; Qiu, Y.; Cao, J.; Li, X.; Luo, X. RETRACTED ARTICLE: Genistein inhibits stemness of SKOV3 cells induced by macrophages co-cultured with ovarian cancer stem-like cells through IL-8/STAT3 axis. J. Exp. Clin. Cancer Res., 2019, 38(1), 19. [http://dx.doi.org/10.1186/s13046-018-1010-1] [PMID: 30646963] [http://dx.doi.org/10.1186/s13046-018-1010-1] [PMID: 30646963] [61] Xu, L.; Xiang, J.; Shen, J.; Zou, X.; Zhai, S.; Yin, Y.; Li, P.; Wang, X.; Sun, Q. Oncogenic MicroRNA-27a is a target for genistein in ovarian cancer cells. Anticancer. Agents Med. Chem., 2013, 13(7), 1126-1132. [http://dx.doi.org/10.2174/18715206113139990006] [PMID: 23438830] [http://dx.doi.org/10.2174/18715206113139990006] [PMID: 23438830] [62] Parker, L.P.; Taylor, D.D.; Kesterson, J.; Metzinger, D.S.; Gercel-Taylor, C. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur. J. Gynaecol. Oncol., 2009, 30(6), 616-621. [PMID: 20099489] [PMID: 20099489] [63] Rusin, A.; Zawisza-Puchałka, J.; Kujawa, K.; Gogler-Pigłowska, A.; Wietrzyk, J.; Świtalska, M.; Głowala-Kosińska, M.; Gruca, A.; Szeja, W.; Krawczyk, Z.; Grynkiewicz, G. Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells. Bioorg. Med. Chem., 2011, 19(1), 295-305. [http://dx.doi.org/10.1016/j.bmc.2010.11.024] [PMID: 21129977] [http://dx.doi.org/10.1016/j.bmc.2010.11.024] [PMID: 21129977] [64] Ning, Y.; Xu, M.; Cao, X.; Chen, X.; Luo, X. Inactivation of AKT, ERK and NF-κB by genistein derivative, 7-difluoromethoxyl-5,4′-di-n-octylygenistein, reduces ovarian carcinoma oncogenicity. Oncol. Rep., 2017, 38(2), 949-958. [http://dx.doi.org/10.3892/or.2017.5709] [PMID: 28627607] [http://dx.doi.org/10.3892/or.2017.5709] [PMID: 28627607] [65] Ning, Y.; Li, Q.; Xiang, H.; Liu, F.; Cao, J. Apoptosis induced by 7-difluoromethoxyl-5,4′-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells. Oncol. Rep., 2012, 27(6), 1857-1864. [PMID: 22447287] [PMID: 22447287] [66] Ning, Y.X.; Li, Q.X.; Ren, K.Q.; Quan, M.F.; Cao, J.G. 7-difluoromethoxyl-5,4′-di-n-octyl genistein inhibits ovarian cancer stem cell characteristics through the downregulation of FOXM1. Oncol. Lett., 2014, 8(1), 295-300. [http://dx.doi.org/10.3892/ol.2014.2080] [PMID: 24959264] [http://dx.doi.org/10.3892/ol.2014.2080] [PMID: 24959264] [67] Ning, Y.X.; Luo, X.; Xu, M.; Feng, X.; Wang, J. Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc. Oncotarget, 2017, 8(43), 74836-74845. [http://dx.doi.org/10.18632/oncotarget.20413] [PMID: 29088827] [http://dx.doi.org/10.18632/oncotarget.20413] [PMID: 29088827] [68] Ahmed, A.A.; Goldsmith, J.; Fokt, I.; Le, X.F.; Krzysko, K.A.; Lesyng, B.; Bast, R.C., Jr; Priebe, W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother. Pharmacol., 2011, 68(4), 1033-1044. [http://dx.doi.org/10.1007/s00280-011-1575-2] [PMID: 21340606] [http://dx.doi.org/10.1007/s00280-011-1575-2] [PMID: 21340606] [69] Wang, J.; Gao, C. Meng Lk: Study on the synthesis and antitumor effects of 5-Hydroxy-4′-nitro-7-propionyloxy-isoflavone. China Pharmacist., 2012, 15, 1378-1385. [70] Jin, Y.; Liu, C.; Wu, Q.; Yao, B.; Dai, Y.; Zhang, L. Design and synthesis of genistein derivatives 5-hydroxy-4′-nitro-7-substituted acyloxy isoflavone and their antitumor effects. Acad. J. Mil. Med. Univ., 2005, 26(2), 182-185. [71] Bai, J.; Luo, X. 5-Hydroxy-4′-nitro-7-propionyloxy-genistein inhibited invasion and metastasis via inactivating wnt/b-catenin signal pathway in human endometrial carcinoma ji endometrial cells. Med. Sci. Monit., 2018, 24, 3230-3243. [http://dx.doi.org/10.12659/MSM.909472] [PMID: 29769480] [http://dx.doi.org/10.12659/MSM.909472] [PMID: 29769480] [72] Bai, J.; Yang, B.J.; Luo, X. Effects of 5-hydroxy-4′-nitro-7-propionyloxy-genistein on inhibiting proliferation and invasion via activating reactive oxygen species in human ovarian cancer A2780/DDP cells. Oncol. Lett., 2018, 15(4), 5227-5235. [http://dx.doi.org/10.3892/ol.2018.7938] [PMID: 29552162] [http://dx.doi.org/10.3892/ol.2018.7938] [PMID: 29552162] [73] Liu, Y.; Zhang, Y-M.; Song, D-F.; Cui, H-B. Effect of apoptosis in human breast cancer cells and its probable mechanisms by genistein. Wei Sheng Yen Chiu, 2005, 34(1), 67-69. [PMID: 15862028] [PMID: 15862028] [74] Hsieh, C-Y.; Santell, R.C.; Haslam, S.Z.; Helferich, W.G. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res., 1998, 58(17), 3833-3838. [PMID: 9731492] [PMID: 9731492] [75] Satoh, H.; Nishikawa, K.; Suzuki, K.; Asano, R.; Virgona, N.; Ichikawa, T.; Hagiwara, K.; Yano, T. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res. Commun. Mol. Pathol. Pharmacol., 2003, 113-114, 149-158. [PMID: 15686114] [PMID: 15686114] [76] Mai, Z.; Blackburn, G.L.; Zhou, J.R. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol. Carcinog., 2007, 46(7), 534-542. [http://dx.doi.org/10.1002/mc.20300] [PMID: 17295235] [http://dx.doi.org/10.1002/mc.20300] [PMID: 17295235] [77] Li, Y.; Ahmed, F.; Ali, S.; Philip, P.A.; Kucuk, O.; Sarkar, F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res., 2005, 65(15), 6934-6942. [http://dx.doi.org/10.1158/0008-5472.CAN-04-4604] [PMID: 16061678] [http://dx.doi.org/10.1158/0008-5472.CAN-04-4604] [PMID: 16061678] [78] Gong, L.; Li, Y.; Nedeljkovic-Kurepa, A.; Sarkar, F.H. Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene, 2003, 22(30), 4702-4709. [http://dx.doi.org/10.1038/sj.onc.1206583] [PMID: 12879015] [http://dx.doi.org/10.1038/sj.onc.1206583] [PMID: 12879015] [79] Caëtano, B.; Le Corre, L.; Chalabi, N.; Delort, L.; Bignon, Y.J.; Bernard-Gallon, D.J. Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines. Br. J. Nutr., 2006, 95(2), 406-413. [http://dx.doi.org/10.1079/BJN20051640] [PMID: 16469160] [http://dx.doi.org/10.1079/BJN20051640] [PMID: 16469160] [80] Seo, H.S.; DeNardo, D.G.; Jacquot, Y.; Laïos, I.; Vidal, D.S.; Zambrana, C.R.; Leclercq, G.; Brown, P.H. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat., 2006, 99(2), 121-134. [http://dx.doi.org/10.1007/s10549-006-9191-2] [PMID: 16541309] [http://dx.doi.org/10.1007/s10549-006-9191-2] [PMID: 16541309] [81] Liu, B.; Edgerton, S.; Yang, X.; Kim, A.; Ordonez-Ercan, D.; Mason, T.; Alvarez, K.; McKimmey, C.; Liu, N.; Thor, A. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res., 2005, 65(3), 879-886. [http://dx.doi.org/10.1158/0008-5472.879.65.3] [PMID: 15705886] [http://dx.doi.org/10.1158/0008-5472.879.65.3] [PMID: 15705886] [82] Manson, M.M.; Farmer, P.B.; Gescher, A.; Steward, W.P. Innovative agents in cancer prevention. Recent Results Cancer Res., 2005, 166, 257-275. [http://dx.doi.org/10.1007/3-540-26980-0_17] [PMID: 15648195] [http://dx.doi.org/10.1007/3-540-26980-0_17] [PMID: 15648195] [83] Kelloff, GJ; Crowell, JA; Steele, VE; Lubet, RA; Malone, WA; Boone, CW Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. J. Nutr., 2000, 2S Suppl, 467s-271s. [84] Kumar, R.; Verma, V.; Jain, A.; Jain, R.K.; Maikhuri, J.P.; Gupta, G. Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J. Nutr. Biochem., 2011, 22(8), 723-731. [http://dx.doi.org/10.1016/j.jnutbio.2010.06.003] [PMID: 21062672] [http://dx.doi.org/10.1016/j.jnutbio.2010.06.003] [PMID: 21062672] [85] Solomon, L.A.; Ali, S.; Banerjee, S.; Munkarah, A.R.; Morris, R.T.; Sarkar, F.H. Sensitization of ovarian cancer cells to cisplatin by genistein: The role of NF-kappaB. J. Ovarian Res., 2008, 1(1), 9. [http://dx.doi.org/10.1186/1757-2215-1-9] [PMID: 19025644] [http://dx.doi.org/10.1186/1757-2215-1-9] [PMID: 19025644] [86] Yanhong, H.; Peng, Y.; Qinghong, Z.; Xiaoyan, X. Genistein sensitizes ovarian carcinoma cells to chemotherapy by switching the cell cycle progression in vitro. J. Med. Coll. PLA, 2009, 24(3), 125-135. [http://dx.doi.org/10.1016/S1000-1948(09)60028-9] [http://dx.doi.org/10.1016/S1000-1948(09)60028-9] [87] Shen, F.; Weber, G. Synergistic action of quercetin and genistein in human ovarian carcinoma cells. Oncol. Res., 1997, 9(11-12), 597-602. [PMID: 9563007] [PMID: 9563007] [88] Rezaei, A.; Fathi, M.; Jafari, S.M. Nanoencapsulation of hydrophobic and low-soluble food bioactive compounds within different nanocarriers. Food Hydrocoll., 2019, 88, 146-162. [http://dx.doi.org/10.1016/j.foodhyd.2018.10.003] [http://dx.doi.org/10.1016/j.foodhyd.2018.10.003] [89] DeLeon, V.H.; Nguyen, T.D.; Nar, M.; D’Souza, N.A.; Golden, T.D. Polymer nanocomposites for improved drug delivery efficiency. Mater. Chem. Phys., 2012, 132(2-3), 409-415. [http://dx.doi.org/10.1016/j.matchemphys.2011.11.046] [http://dx.doi.org/10.1016/j.matchemphys.2011.11.046] [90] Elzoghby, A.O.; Abo El-Fotoh, W.S.; Elgindy, N.A. Casein-based formulations as promising controlled release drug delivery systems. J. Control. Release, 2011, 153(3), 206-216. [http://dx.doi.org/10.1016/j.jconrel.2011.02.010] [PMID: 21338636] [http://dx.doi.org/10.1016/j.jconrel.2011.02.010] [PMID: 21338636] [91] Bindhya, K.P.; Uma Maheswari, P.; Meera Sheriffa Begum, K.M. Milk protein inspired multifunctional magnetic carrier targeting progesterone receptors: Improved anticancer potential of soybean-derived genistein against breast and ovarian cancers. Mater. Chem. Phys., 2021, 272, 125055. [http://dx.doi.org/10.1016/j.matchemphys.2021.125055] [http://dx.doi.org/10.1016/j.matchemphys.2021.125055] [92] Nurunnabi, M.; Khatun, Z.; Badruddoza, A.Z.M.; McCarthy, J.R.; Lee, Y.; Huh, K.M. Biomaterials and bioengineering approaches for mitochondria and nuclear targeting drug delivery. ACS Biomater. Sci. Eng., 2019, 5(4), 1645-1660. [http://dx.doi.org/10.1021/acsbiomaterials.8b01615] [http://dx.doi.org/10.1021/acsbiomaterials.8b01615] [93] Souho, T.; Lamboni, L.; Xiao, L.; Yang, G. Cancer hallmarks and malignancy features: Gateway for improved targeted drug delivery. Biotechnol. Adv., 2018, 36(7), 1928-1945. [http://dx.doi.org/10.1016/j.biotechadv.2018.08.001] [PMID: 30077715] [http://dx.doi.org/10.1016/j.biotechadv.2018.08.001] [PMID: 30077715] [94] Attari, E.; Nosrati, H.; Danafar, H.; Kheiri Manjili, H. Methotrexate anticancer drug delivery to breast cancer cell lines by iron oxide magnetic based nanocarrier. J. Biomed. Mater. Res. A, 2019, 107(11), 2492-2500. [http://dx.doi.org/10.1002/jbm.a.36755] [PMID: 31298774] [http://dx.doi.org/10.1002/jbm.a.36755] [PMID: 31298774] [95] Nosrati, H.; Javani, E.; Salehiabar, M.; Kheiri Manjili, H.; Davaran, S.; Danafar, H. Biocompatibility and anticancer activity of L-phenyl alanine-coated iron oxide magnetic nanoparticles as potential chrysin delivery system. J. Mater. Res., 2018, 33(11), 1602-1611. [http://dx.doi.org/10.1557/jmr.2018.148] [http://dx.doi.org/10.1557/jmr.2018.148] [96] Purushothaman, B.K.; Maheshwari, U.P.; K M, M.S.B. Magnetic casein-CaFe2O4 nanohybrid carrier conjugated with progesterone for enhanced cytotoxicity of citrus peel derived hesperidin drug towards breast and ovarian cancer. Int. J. Biol. Macromol., 2020, 151, 293-304. [http://dx.doi.org/10.1016/j.ijbiomac.2020.02.172] [PMID: 32084471] [http://dx.doi.org/10.1016/j.ijbiomac.2020.02.172] [PMID: 32084471] [97] Kamaraj, S.; Palanisamy, U.M.; Kadhar Mohamed, M.S.B.; Gangasalam, A.; Maria, G.A.; Kandasamy, R. Curcumin drug delivery by vanillin-chitosan coated with calcium ferrite hybrid nanoparticles as carrier. Eur. J. Pharm. Sci., 2018, 116, 48-60. [http://dx.doi.org/10.1016/j.ejps.2018.01.023] [PMID: 29355595] [http://dx.doi.org/10.1016/j.ejps.2018.01.023] [PMID: 29355595] [98] Hussien, N.A.; Işıklan, N.; Türk, M. Aptamer-functionalized magnetic graphene oxide nanocarrier for targeted drug delivery of paclitaxel. Mater. Chem. Phys., 2018, 211, 479-488. [http://dx.doi.org/10.1016/j.matchemphys.2018.03.015] [http://dx.doi.org/10.1016/j.matchemphys.2018.03.015] [99] Diep, C.H.; Daniel, A.R.; Mauro, L.J.; Knutson, T.P.; Lange, C.A. Progesterone action in breast, uterine, and ovarian cancers. J. Mol. Endocrinol., 2015, 54(2), R31-R53. [http://dx.doi.org/10.1530/JME-14-0252] [PMID: 25587053] [http://dx.doi.org/10.1530/JME-14-0252] [PMID: 25587053] [100] Zhou, L.; Zhou, W.; Zhang, H.; Hu, Y.; Yu, L.; Zhang, Y.; Zhang, Y.; Wang, S.; Wang, P.; Xia, W. Progesterone suppresses triple-negative breast cancer growth and metastasis to the brain via membrane progesterone receptor α. Int. J. Mol. Med., 2017, 40(3), 755-761. [http://dx.doi.org/10.3892/ijmm.2017.3060] [PMID: 28713912] [http://dx.doi.org/10.3892/ijmm.2017.3060] [PMID: 28713912] [101] Syed, V.; Mukherjee, K.; Godoy-Tundidor, S.; Ho, S.M. Progesterone induces Apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J. Cell. Biochem., 2007, 102(2), 442-452. [http://dx.doi.org/10.1002/jcb.21304] [PMID: 17393432] [http://dx.doi.org/10.1002/jcb.21304] [PMID: 17393432] [102] Pool, H.; Campos-Vega, R.; Herrera-Hernández, M.G.; García-Solis, P.; García-Gasca, T.; Sánchez, I.C.; Luna-Bárcenas, G.; Vergara-Castañeda, H. Development of genistein-PEGylated silica hybrid nanomaterials with enhanced antioxidant and antiproliferative properties on HT29 human colon cancer cells. Am. J. Transl. Res., 2018, 10(8), 2306-2323. [PMID: 30210672] [PMID: 30210672] [103] Wang, Y.; Li, W.; Wang, Z.; Ren, H.; Li, Y.; Zhang, Y.; Yang, P.; Pan, S. Genistein upregulates cyclin D1 and CDK4 expression and promotes the proliferation of ovarian cancer OVCAR-5 cells. Clin. Chim. Acta, 2021, 512, 100-105. [http://dx.doi.org/10.1016/j.cca.2019.08.023] [PMID: 31465770] [http://dx.doi.org/10.1016/j.cca.2019.08.023] [PMID: 31465770] [104] Hwang, K.A.; Park, M.A.; Kang, N.H.; Yi, B.R.; Hyun, S.H.; Jeung, E.B.; Choi, K.C. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and insulin-like growth factor-1 receptor signaling pathways. Toxicol. Appl. Pharmacol., 2013, 272(3), 637-646. [http://dx.doi.org/10.1016/j.taap.2013.07.027] [PMID: 23933164] [http://dx.doi.org/10.1016/j.taap.2013.07.027] [PMID: 23933164] [105] Gercel-Taylor, C.; Feitelson, A.K.; Taylor, D.D. Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. Anticancer Res., 2004, 24(2B), 795-800. [PMID: 15161029] [PMID: 15161029] [106] Choi, E.J.; Kim, T.; Lee, M.S. Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci., 2007, 80(15), 1403-1408. [http://dx.doi.org/10.1016/j.lfs.2006.12.031] [PMID: 17291540] [http://dx.doi.org/10.1016/j.lfs.2006.12.031] [PMID: 17291540] [107] Novak-Hofer, I.; Cohrs, S.; Grünberg, J.; Friedli, A.; Schlatter, M.C.; Pfeifer, M.; Altevogt, P.; Schubiger, P.A. Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Lett., 2008, 261(2), 193-204. [http://dx.doi.org/10.1016/j.canlet.2007.11.012] [PMID: 18155830] [http://dx.doi.org/10.1016/j.canlet.2007.11.012] [PMID: 18155830] 41 2